Universidad Complutense de Madrid (UCM)

Hybrids Part A: Hybrids for Tissue Regeneration (2021) Zheng K, Salinas AJ, Lao J Journal article, Editorial Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival (2021) Slamon DJ, Neven P, Chia S, Jerusalem G, De Laurentiis M, Im S, Petrakova K, et al. Journal article Association Between FIASMAs and Reduced Risk of Intubation or Death in Individuals Hospitalized for Severe COVID-19: An Observational Multicenter Study (2021) Hoertel N, Sanchez-Rico M, Gulbins E, Kornhuber J, Carpinteiro A, Lenze EJ, Reiersen AM, et al. Journal article A generic curriculum development model for the biomedical physics component of the educational and training programmes of the non-physics healthcare professions (2021) Caruana CJ, Karenauskaite V, Mornstein V, Vano E, Pace E, Lammertsma AA, Maas AJ, et al. Journal article Continuous-Flow Synthesis of High-Quality Few-Layer Antimonene Hexagons (2021) Torres I, Alcaraz M, Sanchis-Gual R, Carrasco JA, Fickert M, Assebban M, Gibaja C, et al. Journal article Detection of the Crab Nebula with the 9.7 m prototype Schwarzschild-Couder telescope (2021) Adams CB, Alfaro R, Ambrosi G, Ambrosio M, Aramo C, Arlen T, Batista PI, et al. Journal article Treatment-related amenorrhea with T-DM1 plus pertuzumab (KP) is lower than with docetaxel/carboplatin/ trastuzumab/pertuzumab (TCHP) in the phase III neoadjuvant KRISTINE trial (2021) Hurvitz SA, Fresco R, Afenjar K, Stroyakovskiy D, Huang CS, Wildiers H, Jung KH, et al. Conference contribution Association of quality of life (QOL) with overall survival (OS) in patients (pts) with HR+/HER2-advanced breast cancer (ABC) treated with ribociclib (RIB) plus endocrine therapy (ET) in the MONALEESA-3 (ML-3) and ML-7 trials (2021) Fasching P, Harbeck N, Jerusalem G, Colleoni MA, Neven P, Franke F, De Laurentiis M, et al. Conference contribution Corrigendum to ‘Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival’: [Annals of Oncology Volume 32, Issue 8, August 2021, Pages 1015-1024] (Annals of Oncology (2021) 32(8) (1015–1024), (S0923753421015532), (10.1016/j.annonc.2021.05.353)) (2021) Slamon DJ, Neven P, Chia S, Jerusalem G, De Laurentiis M, Im S, Petrakova K, et al. Journal article, Erratum Practical postgraduate teaching in Human Anatomy: A review (2021) Sañudo JR, Vázquez T, Talarico EF, Duparc F, Paulsen F, Macchi V, Feigl G, et al. Journal article, Review article